MedCity News January 13, 2020
Joel Berg

According to a report by professional services firm EY, companies that want to grow, focus and innovate will drive dealmaking in 2020, though activity may not reach the record level set in 2019 — $357 billion as of the end of November.

Big pharma drove M&A value in the life-sciences field to a record high in 2019. That record is likely to remain standing, at least for 2020, but companies still face pressure to strike deals, according to an annual report on M&A by professional services firm EY (Ernst & Young).

Biotech companies face challenges in growing revenue; big pharma companies will look to shed non-core therapy lines; and pharmaceutical firms may be eager to snap up cell and gene-therapy...